ST
LCTX icon

Spot Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Spot Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-68,580
Closed -$234K – 2981
2016
Q3 		$234K Hold
68,580
– – ﹤0.01% 1986
2016
Q2 		$157K Buy
+68,580
New +$168K ﹤0.01% 2355
2015
Q4 		– Sell
-24,780
Closed -$60K – 3854
2015
Q3 		$60K Buy
+24,780
New +$64.2K ﹤0.01% 3232

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spot Trading's LCTX Position: Q4 2016 in Review

Spot Trading sold out of Lineage Cell Therapeutics (LCTX) in Q4 2016, closing a stake of 6,505 shares — an estimated $22K sold.

Spot Trading first reported a position in LCTX in Q3 2015 and held it in 3 quarters. The position peaked at $65K in Q2 2016. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • Spot Trading reported no remaining Lineage Cell Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 6,505 Lineage Cell Therapeutics shares in Q4 2016, an estimated $22K.
  • Spot Trading first reported a position in Lineage Cell Therapeutics in Q3 2015 and held it in 3 quarters.
  • Spot Trading's Lineage Cell Therapeutics position peaked at $65K in Q2 2016.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.